FOLH1 and prostate cancer: It has been shown that the GOx cytotoxicity to prostate specific membrane antigen (PSMA)-expressing prostate cancer cells can be enhanced by modifying GOx with cationic co-polymer PLL-g-PEG, which improved the uptake levels in LNCaP cells [108].